FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial. PMID 42015666 · Int J Cancer · 2026-Sep-01 The record describes the CAP randomised trial, which is a large, randomized screening trial for prostate cancer. While it is an oncology, human, randomized trial with long-term time-to-event analysis, it does not meet the core eligibility requirement of being a Phase III/IIIb or Phase II/III trial of a drug-containing intervention. The intervention is a one-off PSA screening test, not a therapeutic drug. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of AI With Anlotinib Versus AI for Treating Synovial Sarcoma Patients With Lung Metastasis: A Retrospective Cohort Study. PMID 41983866 · Int J Cancer · 2026-Sep-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer. PMID 40956129 · Int J Cancer · 2026-Sep-01 The record describes a biomarker and machine learning analysis for predicting prostate cancer aggressiveness and mortality. It is not a randomized controlled trial, does not involve a drug intervention, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, Kaplan-Meier, HR) from a clinical trial. It is excluded based on these criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes and exploratory analysis from a randomized phase 3 trial of radiation dose escalation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. PMID 42442129 · Drug Resist Updat · 2026-Sep 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results. PMID 42441931 · Neurol Neuroimmunol Neuroinflamm · 2026-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S. PMID 42436759 · J Allergy Clin Immunol Glob · 2026-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion. PMID 42325497 · Obes Pillars · 2026-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes. PMID 42119725 · Ann Vasc Surg · 2026-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of air pollution exposure on chronic kidney disease and type 2 diabetes: A FIDELITY analysis. PMID 42403440 · Am J Prev Cardiol · 2026-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Content validity and clinically meaningful change on patient-reported outcome measures for use in obstructive sleep apnea. PMID 42247851 · Sleep Med · 2026-Oct 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial. PMID 42208702 · Magn Reson Imaging · 2026-Oct The abstract describes a secondary biomarker analysis (imaging correlation) from a COG phase III trial, not the primary report of the trial's efficacy results. While it references a phase III trial and EFS, the abstract itself is not the original formal report of the randomized trial's primary efficacy outcome, and key eligibility criteria (explicit randomization, specific drug intervention) are not established in the provided text. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. PMID 42203164 · Am Heart J · 2026-Oct 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial. PMID 42225236 · Ann Oncol · 2026-May-31 Study is a randomized trial in human oncology with a drug intervention and time-to-event endpoints (DFS, OS, recurrence). Phase is not explicitly stated in the record, but it is a definitive randomized trial with primary results, meeting eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. PMID 42223087 · N Engl J Med · 2026-May-31 Meets all eligibility criteria: phase 3, randomized, human oncology trial with a drug intervention and primary time-to-event endpoint (EFS). |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Perioperative Apalutamide in High-Risk Localized Prostate Cancer. PMID 42223077 · N Engl J Med · 2026-May-31 Meets all criteria: oncology, human, randomized, Phase III, drug intervention (apalutamide), original final results with primary/secondary time-to-event endpoints. |
S
B
|
严格 v3 独有 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. PMID 42223072 · N Engl J Med · 2026-May-31 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. PMID 42223064 · N Engl J Med · 2026-May-30 Meets all criteria: oncology, human, randomized Phase III trial with drug-containing intervention (PARP inhibitor + ARSI) and primary/key secondary time-to-event endpoints (PFS, OS). This is an interim analysis of an original trial result. |
S
B
|
严格 v3 独有 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial. PMID 42218963 · Ann Oncol · 2026-May-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Long-Term Sedation Effect of Cipepofol Compared to Dexmedetomidine in Patients Receiving Invasive Mechanical Ventilation: A Multicenter, Randomized, Open-Label, Parallel-Controlled Study. PMID 42217116 · Adv Ther · 2026-May-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study. PMID 42208564 · Lancet · 2026-May-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. PMID 42208561 · Lancet · 2026-May-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. PMID 42208560 · Lancet · 2026-May-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. PMID 41865758 · Lancet · 2026-May-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. PMID 42217582 · Ann Oncol · 2026-May-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab versus pembrolizumab in the treatment of advanced triple-negative breast cancer: a Bayesian network meta-analysis of ITT and PD-L1 positive populations. PMID 42215937 · BMC Cancer · 2026-May-29 The record is a meta-analysis (a review of existing trials) and not an original result report from a single randomized trial. Furthermore, the primary endpoints are not the standard time-to-event outcomes (OS, PFS, etc.) as explicitly required by the adjudication criteria. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of an artificial intelligence (AI)-assisted education program on mental health, social support and quality of life in older individuals with head and neck cancer: study protocol of a randomized controlled trial. PMID 42215892 · BMC Geriatr · 2026-May-29 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial. PMID 42215378 · Gynecol Oncol · 2026-May-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. PMID 42212913 · N Engl J Med · 2026-May-29 The record explicitly describes a phase 3 international trial with random assignment (1:1), a primary time-to-event efficacy endpoint (PFS with HR), a drug-containing intervention (sunvozertinib vs. chemotherapy), and presents the original primary result of the trial. It meets all criteria for inclusion. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Intensive Versus Conventional Blood Pressure Lowering After Successful Endovascular Thrombectomy: OPTIMAL-BP 1-Year Outcomes. PMID 42212393 · Stroke · 2026-May-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Finafloxacin Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa: Results from two Phase III Randomized Clinical Studies. PMID 42210509 · Ann Otol Rhinol Laryngol · 2026-May-28 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Research waste among randomized controlled trials of delirium: A cross-sectional study. PMID 42209336 · Int Psychogeriatr · 2026-May-28 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Traumatic Inflammatory-Coagulation Coactivation Occurs Early After Injury and Impacts Mortality. PMID 42206924 · Crit Care Med · 2026-May-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Oleogel-S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa. PMID 42205007 · Pediatr Dermatol · 2026-May-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. PMID 42202319 · N Engl J Med · 2026-May-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Lifestyle Program for Breast Cancer Improves Body Composition, Fitness, and Patient-Reported Outcomes: A Randomized Clinical Trial. PMID 42279341 · Cancers (Basel) · 2026-May-27 The record describes a randomized trial of a non-drug lifestyle intervention in oncology, reporting secondary patient-reported and physiological outcomes. It does not meet the required criteria for a drug intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of RTS, S and R21 malaria vaccines in children under five in Africa: a systematic review and meta-analysis of randomized controlled trials. PMID 42204567 · Malar J · 2026-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin-naïve Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.009. PMID 42203610 · Eur Urol Focus · 2026-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.01.009. PMID 42203609 · Eur Urol Focus · 2026-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of Telemedicine Follow-Up Visits in Children With Cancer Undergoing Intensive Chemotherapy: Results From the Randomized KULT-SH Trial. PMID 42202247 · JCO Oncol Pract · 2026-May-27 The study is a randomized Phase III trial in oncology patients with drug intervention, but it lacks a primary time-to-event efficacy endpoint. The primary endpoint is a safety/comparative effectiveness endpoint (adverse events), not a survival or progression metric. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The RAINBOW study: a phase 2 trial evaluating the 3-month pharmacokinetic and pharmacodynamic data and 18-month clinical and safety outcomes of nizubaglustat in GM2 gangliosidoses or Niemann-Pick type C disease. PMID 42308595 · Mol Genet Metab · 2026-May-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. PMID 42192224 · Chin Med J (Engl) · 2026-May-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trial. PMID 42186075 · Trials · 2026-May-26 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Circulating tumor DNA-based assessment of disease progression after liver resection or transplantation for metastatic colorectal cancer or hepatocellular carcinoma-study protocol for a randomized, controlled trial. PMID 42185926 · Trials · 2026-May-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study. PMID 41779961 · Blood Adv · 2026-May-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis. PMID 41206702 · Clin Exp Dermatol · 2026-May-26 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial. PMID 42186031 · J Ovarian Res · 2026-May-25 The study is a single-arm, open-label phase IIIb trial, not a randomized controlled trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis. PMID 42185290 · Nat Commun · 2026-May-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma. PMID 42184925 · Ann Hepatol · 2026-May-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Improving the Understanding of Late Effects of Testicular Cancer in Adolescent and Young Adult Survivors: TRANSCEND-XR. PMID 42179065 · Andrology · 2026-May-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A comparative analysis of parametric, semiparametric and machine learning models for survival prediction. PMID 42178520 · BMC Med Res Methodol · 2026-May-25 The record is a methodological comparative analysis of survival models using data from a Phase III trial, not an original report of a randomized trial with a drug intervention and primary efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
第 1 / 419 页
下一页